Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 2 of 12 for:    TL32711

Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma

This study has been completed.
Information provided by (Responsible Party):
TetraLogic Pharmaceuticals Identifier:
First received: October 8, 2009
Last updated: March 1, 2016
Last verified: March 2016
A Phase 1 open-label, non-randomized dose escalation study to determine the maximum tolerated dose (MTD) and characterize the safety and tolerability of Birinapant (TL32711).

Condition Intervention Phase
Drug: Birinapant (TL32711)
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1, Open-Label, Non-randomized, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TL32711 in Adults With Refractory Solid Tumors or Lymphoma

Resource links provided by NLM:

Further study details as provided by TetraLogic Pharmaceuticals:

Primary Outcome Measures:
  • Define the MTD [ Time Frame: 4 weeks (Cycle 1) ]

Secondary Outcome Measures:
  • Tumor burden according to Response Evaluation Criteria in Solid Tumors (RECIST)/Revised Response Criteria Malignant Lymphoma [ Time Frame: Every 8 weeks (2 cycles) while on treatment ]
  • Translational biomarkers and pharmacokinetics [ Time Frame: First and third dose of Cycle 1 and after every two cycles (biomarkers only) while on treatment ]

Enrollment: 50
Study Start Date: November 2009
Study Completion Date: March 2013
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Birinapant (TL32711) Drug: Birinapant (TL32711)
30 minute intravenous (IV) infusion administered once weekly for three consecutive weeks followed by a one week off (Cycle) repeated every 4 weeks as tolerated
Other Name: NSC 756502

Detailed Description:
The purpose of this Phase 1 open-label, non-randomized dose escalation study is to determine the maximum tolerated dose (MTD) and characterize the safety and tolerability of Birinapant (TL32711) when administered as a 30 minute intravenous infusion once weekly for three weeks per repeated 4 week intervals in subjects with refractory solid tumors or lymphoma. Additionally study will assess anti-tumor activity, pharmacokinetics, and exploratory biomarkers as a measurement of pharmacodynamic effects.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Advanced metastatic or unresectable malignancy that is refractory to currently available standard therapies or no effective therapy exists. The subject's malignancy must be confirmed by prior pathologic study.
  • Evaluable disease (measurable or non-measurable) by Response Evaluation Criteria in Solid Tumors (RECIST, Version 1.1) or Revised Response Criteria for Malignant Lymphoma (RRCML) (Cheson 2007).
  • Life expectancy greater than 3 months.
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
  • Adequate renal function, defined as serum creatinine ≤ 1.5 X upper limit of normal (ULN), or calculated creatinine clearance ≥ 60 ml/min.
  • Adequate hepatic function, defined as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤ 3 X ULN and total bilirubin < 1.5 X ULN.
  • Adequate bone marrow function, defined as absolute neutrophil (ANC) ≥ 1,500/mm3 (≥1.5 X106/L), platelet count ≥ 75,000/mm3 (≥ 75 X106/L), and hemoglobin ≥ 10 mg/dL in the absence of transfusion.

Key Exclusion Criteria:

  • Recent anti-cancer treatment defined as:

    • Standard or investigational anti-cancer therapy within 4 weeks prior to first dose of TL32711. Exception: continued hormonal interventions for sensitive diseases.
    • Radiation therapy within 2 weeks prior to the first dose of TL32711.
  • Clinically significant pulmonary illness resulting in Grade ≥ 2 hypoxia (National Cancer Institute Common Terminology criteria for Adverse Events [NCI CTCAE, v4]) or any requirement for supplemental oxygen, or pulse oximetry less than 90% saturation on room air.
  • Symptomatic or uncontrolled brain metastases requiring current treatment (less than 4 weeks from last cranial radiation or 2 weeks from last steroids).
  • Impaired cardiac function or clinically significant cardiac disease.
  • Ongoing auto-immune disease or with history of an auto-immune disease within the past 5 years. Auto-immune disease include but are not limited to systemic lupus erythematosis, scleroderma, rheumatoid arthritis, psoriasis, psoriatic arthritis, ulcerative colitis and regional enteritis (Crohn's disease).
  • Systemic or chronic topical corticosteroids or immunosuppressive therapy within 4 weeks prior to study entry or anticipated need of systemic corticosteroids or immunosuppressive therapy during study participation.
  • Skin lesions of Grade ≥ 2 severity (NCI CTCAE v4), except alopecia.
  • Lack of recovery of prior adverse events to Grade ≤1 severity (NCI CTCAE v 4) (except alopecia or neuropathy) due to medications administered prior to the first dose of TL32711.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00993239

United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
United States, Pennsylvania
University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania, United States, 19104
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
Sponsors and Collaborators
TetraLogic Pharmaceuticals
Principal Investigator: Ravi Amaravadi, MD University of Pennsylvania, Abramson Cancer Center
Principal Investigator: Lainie P Martin, MD Fox Chase Cancer Center
Principal Investigator: Alex Adjei, MD, PhD Roswell Park Cancer Institute
  More Information

Responsible Party: TetraLogic Pharmaceuticals Identifier: NCT00993239     History of Changes
Other Study ID Numbers: TL32711-FIH-007-PTL-F
Study First Received: October 8, 2009
Last Updated: March 1, 2016 processed this record on April 25, 2017